Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Egger

Showing results (641-650 of 656) with videos related to

Pageof 66
Sort By:
Mycopathologia|August 11, 2023
Predictors for Prolonged Hospital Stay Solely to Complete Intravenous Antifungal Treatment in Patients with Candidemia: Results from the ECMM Candida III Multinational European Observational Cohort StudyMatthias Egger, Jon Salmanton-García, Aleksandra Barac, et al.
International Journal of Cancer|June 20, 2019
Cervical cancer risk in women living with HIV across four continents: A multicohort studyEliane Rohner, Lukas Bütikofer, Kurt Schmidlin, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 20, 2016
When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries: A Prospective Observational StudyEllen C Caniglia, Caroline Sabin, James M Robins, et al.
The Lancet. Oncology|October 26, 2016
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trialSalah-Eddin Al-Batran, Ralf D Hofheinz, Claudia Pauligk, et al.
Wellcome Open Research|July 22, 2024
Trace amine-associated receptor 1 (TAAR1) agonism for psychosis: a living systematic review and meta-analysis of human and non-human dataSpyridon Siafis, Virginia Chiocchia, Malcolm R Macleod, et al.
The Journal of Infection|October 17, 2025
Risk factors for persistent candidemia and prognostic implications: Results from the ECMM Candida III studySarah Sedik, Matthias Egger, Stella Wolfgruber, et al.
Plos Pathogens|April 4, 2023
Back-to-Africa introductions of Mycobacterium tuberculosis as the main cause of tuberculosis in Dar es Salaam, TanzaniaMichaela Zwyer, Liliana K Rutaihwa, Etthel Windels, et al.
Statistics in Medicine|March 19, 2019
Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV-positive individualsEllen C Caniglia, James M Robins, Lauren E Cain, et al.
The Lancet. HIV|April 16, 2017
Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational studyEllen C Caniglia, Lauren E Cain, Caroline A Sabin, et al.
Lancet (London, England)|April 16, 2019
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trialSalah-Eddin Al-Batran, Nils Homann, Claudia Pauligk, et al.
Pageof 66

Showing results (641-650 of 656) with videos related to

Sort By:
Pageof 66
Mycopathologia|August 11, 2023
Predictors for Prolonged Hospital Stay Solely to Complete Intravenous Antifungal Treatment in Patients with Candidemia: Results from the ECMM Candida III Multinational European Observational Cohort StudyMatthias Egger, Jon Salmanton-García, Aleksandra Barac, et al.
International Journal of Cancer|June 20, 2019
Cervical cancer risk in women living with HIV across four continents: A multicohort studyEliane Rohner, Lukas Bütikofer, Kurt Schmidlin, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 20, 2016
When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries: A Prospective Observational StudyEllen C Caniglia, Caroline Sabin, James M Robins, et al.
The Lancet. Oncology|October 26, 2016
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trialSalah-Eddin Al-Batran, Ralf D Hofheinz, Claudia Pauligk, et al.
Wellcome Open Research|July 22, 2024
Trace amine-associated receptor 1 (TAAR1) agonism for psychosis: a living systematic review and meta-analysis of human and non-human dataSpyridon Siafis, Virginia Chiocchia, Malcolm R Macleod, et al.
The Journal of Infection|October 17, 2025
Risk factors for persistent candidemia and prognostic implications: Results from the ECMM Candida III studySarah Sedik, Matthias Egger, Stella Wolfgruber, et al.
Plos Pathogens|April 4, 2023
Back-to-Africa introductions of Mycobacterium tuberculosis as the main cause of tuberculosis in Dar es Salaam, TanzaniaMichaela Zwyer, Liliana K Rutaihwa, Etthel Windels, et al.
Statistics in Medicine|March 19, 2019
Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV-positive individualsEllen C Caniglia, James M Robins, Lauren E Cain, et al.
The Lancet. HIV|April 16, 2017
Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational studyEllen C Caniglia, Lauren E Cain, Caroline A Sabin, et al.
Lancet (London, England)|April 16, 2019
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trialSalah-Eddin Al-Batran, Nils Homann, Claudia Pauligk, et al.
Pageof 66